<DOC>
	<DOCNO>NCT01698138</DOCNO>
	<brief_summary>This study double blind , randomize , placebo control trial explore effect early treatment Onabotulinumtoxin A patient acute complete motor spinal cord injury ( SCI ) development neurogenic detrusor overactivity ( NDO ) . A total 20 patient randomize intra-detrusor injection 300 U Onabotulinumtoxin A 30 ml NaCl 0.9 % placebo 30 ml NaCl 0.9 % . Bladder biopsy obtain procedure . The treatment repeat three month . All include patient evaluate urodynamic examination . Follow-up 12 month first treatment . The primary endpoint study development NDO .</brief_summary>
	<brief_title>Prevention Bladder Dysfunction Acute Spinal Cord Injury</brief_title>
	<detailed_description />
	<mesh_term>Wounds Injuries</mesh_term>
	<mesh_term>Spinal Cord Injuries</mesh_term>
	<mesh_term>Urinary Bladder , Overactive</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<criteria>Patients document acute , motor complete C6 Th11 spinal cord injury Patients include study less four week injury Male female , age 18 80 year old Patient weight &gt; 40 kg Patient able willing sign inform consent Patient able complete study requirement Neurogenic detrusor overactivity contraction great 40 cm H2O first visit History evidence previous urological abnormality , disease surgery , except bladder dysfunction spinal cord injury History haematuria ongoing haematuria , hematuria determine pathologic condition uninvestigated Pregnancy female childbearing potential unwilling use reliable form contraception Breastfeeding Known allergy Onabotulinumtoxin A Grave psychiatric disorder Use antiplatelet anticoagulant low molecular weight heparin ( LMWH ) acetylsalicylic acid Haemophilia clot disorder cause bleed diathesis Treatment antimuscarinic medication within 3 month randomization Treatment botulinum toxin serotype within 3 month randomization Patient immunize botulinum toxin serotype Patient medical condition may put patient increase risk exposure botulinum toxin include diagnose myasthenia gravis , EatonLambert syndrome amyotrophic lateral sclerosis Patient condition situation , , investigator 's opinion , put patient significant risk , could confound study result , may interfere significantly patient 's participation study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Spinal cord injury</keyword>
	<keyword>Neurogenic overactive bladder</keyword>
	<keyword>Onabotulinum toxin A</keyword>
	<keyword>Prevention</keyword>
	<keyword>Botulinum Toxins , Type A</keyword>
</DOC>